Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Alto Neuroscience Inc. (ANRO:NYSE), powered by AI.
Alto Neuroscience Inc. is currently trading at $26.72. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Alto Neuroscience Inc. on Alpha Lenz.
Alto Neuroscience Inc.'s P/E ratio is -12.2.
“Alto Neuroscience Inc. trades at a P/E of -12.2 (undervalued) with modest ROE of -41.8%.”
Ask for details →Alto Neuroscience Inc. is a biotechnology company that focuses on developing precision therapeutics for psychiatric disorders. The company's primary objective is to utilize advanced neurobiological insights and digital tools to tailor treatments for conditions like depression, anxiety, and other mental health disorders. Utilizing cutting-edge techniques such as AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience seeks to enhance the efficacy of mental health treatments by ensuring more personalized and targeted solutions. This approach represents a significant innovation in the mental health sector by moving away from the one-size-fits-all model of psychotropic medications. In terms of market impact, Alto Neuroscience operates at the intersection of biotechnology and digital health, playing a pivotal role in the evolution of psychiatric treatment paradigms. The company's efforts contribute to the broader healthcare landscape by potentially improving patient outcomes and reducing trial and error in mental health medication management.
“Alto Neuroscience Inc. trades at a P/E of -12.2 (undervalued) with modest ROE of -41.8%.”
Ask for details →Alto Neuroscience Inc. (ticker: ANRO) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 76 employees. Market cap is $771M.
The current price is $26.72 with a P/E ratio of -12.19x and P/B of 5.1x.
ROE is -41.80%.